Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Breast cancer highlights

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial